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Abstract  
The intestinal tract mucosa is exposed to a vast number of environmental antigens and a large 
community of commensal bacteria. The mucosal immune system has to provide both 
protection against pathogens and tolerance to harmless bacteria. Immune homeostasis 
depends on the interaction of indigenous commensal and transient bacteria (probiotics) with 
various components of the epithelium and the gut-associated lymphoid tissue (GALT). 
Herein, an update is given of the mechanisms by which the gut microbiota and probiotics are 
translocated through the epithelium, sensed via pattern-recognition receptors, and activate 
innate and adaptive immune responses.  
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Introduction 
The intestinal tract mucosa is exposed to a vast number of environmental antigens acquired 
orally and a large community of commensal bacteria. Herein, the epithelium, the mucosal 
immune system and the gut microbiota orchestrate a network of immunological and non-
immunological defences, providing both protection against pathogens and tolerance to 
commensal bacteria and harmless antigens. The intestinal epithelium constitutes a physical 
barrier that excludes most of the antigens prior to immune activation. The primary defensive 
mechanisms also include the production of mucus and other secretions, regulation of 
paracellular permeability and synthesis of antimicrobial peptides. In addition, the epithelium 
and the gut-associated lymphoid tissue (GALT) develop complex immune responses to 
different stimuli, which involve the production of cytokines, chemokines and different 
effector and regulatory T cells, which ensure pathogen elimination without causing tissue 
damage in physiological conditions.   
The gut microbiota and transient bacteria (probiotics) are known to influence the 
development and regulation of the host’s defences, of immune and non-immune nature. 
Commensal bacteria regulate mucin gene expression (e.g. MUC-2 and MUC-3 genes) by 
goblet cells and modify the glycosylation pattern, which may affect bacterial adhesion, 
colonization and invasion [1, 2]. Some commensal bacteria also induce the secretion of 
antimicrobial peptides (defensins and angiogenins) by intestinal Paneth cells [3, 4] and 
regulate the alterations of permeability associated with infections, stress and inflammatory 
conditions [5]. Moreover, comparisons between germ-free and colonized mice showed that 
microbiota has an enormous impact on the development of mucosal and systemic immunity 
In germ-free mice, the GALT was immature, with a low content of lamina propria T cells, 
immunoglobulin (Ig) A producing B cells and intraepithelial T cells. Absence of the 
microbiota also affected systemic immunity since germ-free mice had decreased serum 
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immunoglobulin levels and smaller spleens [6]. These differences disappeared after 
colonization with the commensal microbiota or administration of bacterial components, 
which are ligands of innate immune cell receptors [7]. Some probiotic bacteria can also 
stimulate the immune system enough to enhance defences against acute infections and 
improve certain chronic inflammatory bowel conditions in humans [8-11]. Herein, the 
mechanism by which the gut microbiota and probiotics are translocated and interact with 
components of the epithelium and the GALT, thereby regulating the host’s innate and 
adaptive immune responses, are reviewed. 
 
Intestinal epithelium and mucosal immune system  
The intestinal epithelium is a selective barrier that separates the luminal content from the 
immune cells of the underlying lamina propria. It consists of a single layer of epithelial cells, 
which include enterocytes (representing 90-95%), mucus-secreting goblet cells, 
enteroendocrine cells and Paneth cells secreting antimicrobial peptides and proteins. The 
intestinal epithelial cells (IECs) develop a barrier function of non-immunologic nature that 
involves secretion of mucus and antimicrobial peptides (e.g. defensins and angiogenins) and 
regulation of cell turnover and integrity. Absorptive cells are involved in the transport and 
internalization of substances (transcytosis) by non specific and specific receptor-mediated 
mechanisms. In this way, IECs import luminal nutrients and antigens, and release IgA into 
the lumen [12]. IECs are also sealed by tight junctions, which regulate the paracellular 
transport of specific substances. In addition, the IECs also develop immune functions and 
express co-stimulatory molecules and components of the human major histocompatibility 
complex, (MHC) and produce inflammatory mediators in response to a stimulus (e.g. TNF, 
IL8, MCP-1, etc.). IECs participate in the initiation and regulation of the mucosal immune 
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response via interactions with professional immune cells found in the epithelium and lamina 
propria, a layer of connective tissue supporting the epithelium [13].  
The GALT consists of variety of cells (lymphocytes, dendritic cells [DCs], macrophages, 
etc.), often grouped in organised structures such as Peyer’s Patches (PPs), mesenteric 
lymphoid nodes (MLN), and isolated lymphoid follicles [14]. Intestinal PPs are more 
permeable to bacteria than other epithelial areas since they lack an overlying brush border, 
mucoid glycocalyx and hydrolytic enzymes, which are characteristic of absorptive 
epithelium, and have specialised transport cells, such as M cells and DCs [15]. Immune cells 
include B lymphocytes (memory cells and plasma cells), of which 70-90% produce type A 
immunoglobulins, and T lymphocytes, which are classified as CD4+ (helper or inducer) and 
CD8+ (suppressor or cytotoxic) cells. CD4+ lymphocytes are mainly in the lamina propria 
while CD8+ lymphocytes are mainly in the epithelia (intraepithelial T cells).   
The first portal of entry of antigens is through enterocytes, M cells and DCs. Epithelial cells 
and antigen presenting cells (DCs and macrophages) express pattern-recognition receptors, 
which are responsible for the initial recognition of specific microbial components (pathogen-
associated molecular patterns) and the discrimination between pathogens and harmless 
microbes and the development of appropriate innate and acquired immune responses [16]. 
These receptors include the Toll-like receptor family (TLRs), which are located at the cell 
surface (e.g. TLR 1, 2, 4 and 5) and intracellularly (e.g. TLR3, 7, 8 and 9), and Nod-like 
receptors (NLRs), which are located intracellularly [17, 18]. For example, TLR2 recognizes 
lipoteichoic acids (LTA) from Gram-positive bacteria, TLR4 recognizes lipopolysaccharide 
(LPS) from Gram-negative bacteria, TLR9 recognizes special sequences of DNA 
(unmethylated CpG motifs), TLR5 recognizes flagellin and NLRs appear to recognize 
bacterial peptidoglycans (Fig. 1). TLRs are transmembrane proteins that upon-ligand binding 
promote signal divergence via interactions with different adaptor proteins (MyD88, 
 6
MAL/TIRAP, TRIF/TICAM-1, TRAM/TIRP/TICAM-2), thereby activating three major 
signalling pathways: nuclear factor (NF)-κB, the mitogen-activated protein kinases (MAPKs) 
and interferon regulatory factors (IRFs) (Fig 1.)  [19]. This leads to the expression of 
inflammatory genes, including those encoding cytokines, cytokines receptors, 
immunoregulatory proteins, adhesion molecules, stress-associated proteins and other 
mediators. Overall these molecules are involved in the recruitment of other immune cells (T 
cells, basophils, neutrophils, dendritic cells and natural killer cells) and in promoting 
inflammatory responses that can lead to pathogen clearance. NOD1 and NOD2 are the best-
characterized NLRs and play a role in detecting of intracellular microorganisms. NOD1 is 
expressed in all cell types and required for NF-κB activation by Gram-negative bacterial 
infection, once the bacteria have bypassed TLR activation [20]. NOD2 is expressed in 
monocytes/macrophages and DCs and is induced in intestinal epithelial cells by TNF-α. 
NOD2 mutations are associated with defective IL-10 production and Crohn’s disease [21].  
Signalling through TLR also stimulates the maturation of DCs, inducing their antigen 
presentation ability, switching on the chemokine receptor program and allowing cells to 
migrate into draining MLN, where they present antigens to naïve T and B cells. T-cell 
differentiation into Th1, Th2 or regulatory T cells (Th3/Tr1) is also thought to depend on the 
type of TLRs involved and cytokine production (Fig. 2). Th1-biased responses, characterized 
by overproduction of IFN-γ, IL-2, and IL-12 cytokines, are associated with inflammatory 
reactions and clearance of intracellular pathogens as well as with chronic inflammatory bowel 
disease such as Crohn’s disease. Most TLR-activated DCs induce differentiation of naïve 
CD4+ T cells into Th1 cells, providing high levels of the Th1-polarizing cytokine IL-12, 
whereas TLR5 and TLR2-activated DCs may promote the differentiation of Th2-cells or 
regulatory T cells by producing high levels of anti-inflammatory cytokine IL-10 and low 
levels of IL-2 [19, 22]. Antigen-specific regulatory T cells include different subtypes of 
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CD4+ T cell: T regulatory 1 (Tr1) cells, which secrete high levels of IL-10, no IL-4, and no 
or low levels of IFN-γ; and T helper 3 (Th3) cells, which secrete high levels of TGF-β [23]. 
In the absence of inflammation, a balance between effector and regulatory lymphocyte 
subpopulations is maintained through a tightly controlled cytokine network. Both IL-10 and 
TGF-β are important cytokines in directing naïve T cell maturation to the generation of 
regulatory T cells. 
 
Translocation of commensal and probiotic bacteria  
Translocation of certain numbers of indigenous bacteria to the MLN seems to be a 
physiological process, which allows the interaction of luminal bacteria with immune 
competent cells, underlying the epithelium, and the induction of different immune responses. 
In pathogen-free mice challenged with intestinal doses of commensal bacteria, small numbers 
of commensals were shown to bind to the luminal side of the M cells, penetrate the epithelial 
cell layer and survive within DCs of intestinal MLN [24]. After capture by DCs, the 
activation of IgA responses was triggered locally and at distant mucosal sites, which may 
contribute to the role of commensal and probiotic bacteria in the neutralization of noxious 
antigens and pathogens as well as in the development of tolerance to harmless bacteria [25].  
Enterobacter cloacae, used as a model of commensal bacteria and administrated to mice, was 
shown to be sampled by M cells in PP and then phagocytosed by CD11c+ DC, which  were  
activated and expressed different co-stimulatory molecules such as CD86 [25]. The probiotic 
E. coli Nissle 1917 was also shown to be translocated into PP and MLN after oral 
administration to mice [26]. Lactobacillus casei strain Shirota was incorporated to M cells of 
PP and digested by innate immune cells to form bioactive components [27]. These bioactive 
components were then recognized through TLR2 in antigen-presenting cells, which thus 
became able to produce different cytokines and, especially, TNF-α. Moreover, the expression 
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level and/or the phosphorylation of some proteins in PPs and MLN were modified by the 
ingestion of the probiotic. In weaned piglets fed with a strain of Bifidobacterium animalis, 
DNA from Bifidobacterium was also detected in MLN and its concentration increased as the 
probiotic dose increased [28]. L. plantarum Lp6 intake was also able to modify the gene 
expression of jejunal Peyer’s patches, including genes involved in immune response, cell 
differentiation, cell–cell signalling, cell adhesion, and signal transcription and transduction 
[15]. 
  
TLR expression and signalling  
TLR expression, localization and signalling in IECs and immune cells are critical to mucosal 
immune activation in the gut, and constitute key elements regulated by the indigenous 
microbiota and probiotic bacteria (Fig 1). 
In recent years, several studies have reported that Gram-negative and Gram-positive bacteria, 
as well as commensal and pathogenic bacteria, differently influence TLR expression and, 
thereby, their mediated immune responses. In mice, Gram-positive bacteria (L. acidophilus 
CRL 924, L. delbrueckii subsp. bulgaricus CRL 423 and the probiotic L. casei CRL 431) 
increased the number of TLR2 positive cells, while Gram-negative bacteria (E. coli 129 and 
E. coli 13-7) increased that of TLR4 positive cells parallel to different cytokine induction (IL-
10 versus IL-12) [29]. L. plantarum BFE 1685, isolated from a child's faeces, and the 
probiotic strain L. rhamnosus GG, but not S. enterica serovar Typhimurium, up-regulated 
TLR2 and TLR9 transcription levels in HT29 cells [30]. Moreover, protein levels of TLR2 
and TLR5 were enhanced by the lactobacilli strains [30]. The Gram-negative probiotic strain 
E. coli Nissle 1917 in co-culture with human T cells increased TLR2 and TLR4 protein 
expression and NF-κB activity. In wild-type mice, but not in TLR2 or TLR4 knockout mice, 
this probiotic ameliorated colitis and decreased pro-inflammatory cytokine secretion, 
 9
suggesting that the effects were mediated via TLR2- and TLR4-dependent pathways [31]. 
However, Gram-positive probiotic bacteria mainly induce TLR2 expression via interactions 
with LTAs [32], but not TLR4 expression. For example, the administration of an aggregating 
strain of L. crispatus M247 to mice increased TLR2 mRNA levels and reduced TLR4 mRNA 
and protein levels in the colonic mucosa through an extracellular signal-regulated kinase-1 
(ERK1) tyrosine phosphorylation-dependent pathway [33]. In colonic epithelial cells, pre-
exposure to L. crispatus M247 also inhibited the LPS-induced IL-6 release and enhanced 
TLR2-mediated IL-10 up-regulation. When mice were administered a strain of B. animalis 
together with fructo-oligosaccharides the dose of B. animalis linearly influenced TLR2 gene 
expression in the lymph nodes and the bifidobacterial DNA negatively correlated with the 
TNF-α gene expression [28]. Despite sharing certain features, Gram-positive pathogenic and 
commensal bacteria influence TLR expression differently. Both L. rhamnosus GG and the 
human pathogen Streptococcus pyogenes enhanced TLR2 expression in macrophages and 
required TLR2 for NF-κB activation. However, only the pathogenic S. pyogenes up-regulated 
TLR3 and TLR7 gene expression [34]. 
DNA of probiotic bacteria also modulates TLR9 expression and thereby elicits a differential 
response in epithelial and immune cells compared with DNA of pathogenic bacteria in vitro 
and in vivo [35, 36]. Exposure of HT-29 cells to DNA of pathogenic strains of Salmonella 
and E. coli led to a significant increase in TLR9 mRNA expression and Salmonella enterica 
serovar Dublin DNA also increased surface TLR9 protein and IL-8 secretion, whereas 
exposure to Bifidobacterium breve DNA did not elicit any change in mRNA levels or TLR9 
localization [36]. The DNA from some probiotic bacteria also limited epithelial pro-
inflammatory responses in vivo and in vitro via TLR9 modulation. In HT-29 cells subjected 
to pro-inflammatory stimuli, DNA from the probiotic mixture VSL3 inhibited IL-8 secretion, 
reduced p38 MAPK expression, delayed NFκB activation, stabilized levels of IκB, and 
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inhibited proteasome function [35]. In wild-type mice, VSL3 DNA attenuated a systemic 
release of TNF-α in response to E. coli DNA injection and, in IL-10-deficient mice, oral 
VSL3 DNA administration led to a reduction in mucosal secretion of TNF-α and IFN-γ, 
improving the histological disease via TLR9 signalling [35].   
Commensal bacteria and some probiotics also influence the expression of negative regulators 
of TLR-mediated immune activation, such as the Toll-interacting protein Tollip, the 
peroxisome-proliferator-activated receptor (PPAR)γ and the A20 protein. Prolonged 
incubation of IECs with TLR ligands (LPS and LTA), resulted in a state of 
hyporesponsiveness associated with increased Tollip mRNA. This would suggest that 
exposure to commensal bacteria could regulate the expression of this negative regulator, 
which inhibits signalling via TLR2 and TLR4 and suppresses LPS-induced IL-1 receptor 
associated kinase (IRAK) phosphorylation and activity, impairing transcriptional activity of 
NFκB and AP-1. AP-1. This mechanism could therefore contribute to intestinal homeostasis 
[37]. PPAR-γ is a member of the steroid-receptor family, which plays a major role in 
maintaining intestinal mucosa homeostasis and whose expression and function are modulated 
by TLR signalling and the gut microbiota. B. thetaiotaomicron induces PPAR-γ expression 
and triggers PPAR-γ mediated nuclear export of the transcriptionally active RelA subunit of 
the NF-κB, attenuating the inflammatory effects induced by Salmonella enteritidis in IECs 
[38]. L. crispatus M247 supplementation in mice was also shown to increase PPAR-γ levels 
and reduce activity of an NFκB-responsive element in the colonic mucosa [39]. This strain 
uses H2O2 as a signal transducing molecule to induce PPAR-γ activation in IECs. A20 protein 
is another negative regulator of NFκB and TLR signalling that is inducible by cytokines. The 
administration of B. lactis Bb12, but not of B. vulgatus, to rats stimulated A20 mRNA 
expression in primary and IECs lines. 
 [40].  
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The gut microbiota also regulates the activation of different components of the TLR 
signalling pathways. Commensal bacteria and some probiotics attenuate the pro-
inflammatory responses by transient activation or inhibition of the NF-κB signalling pathway 
at different steps. B. thetaiotaomicron acts downstream NFkB activation by promoting 
nuclear export of NF-κB subunit relA in complex with PPAR-γ as indicated above [38], 
while other commensal bacteria block NFkB at more proximal steps, inhibiting ubiquitination 
and proteolytic inactivation of the endogenous NF-κB inhibitor IκB [41]. Moreover, the 
probiotic strain L. reuteri ATCC PTA 6475 can suppress TNF production by LPS-activated 
monocytes and primary monocyte-derived macrophages from children with Crohn's disease 
by inhibiting the activation of MAP kinase-regulated c-Jun and the transcription factor AP-1 
[42]. Exposure of IECs to bacterial LPS has also been shown to induce TLR tolerance in 
these cells via posttranscriptional down-regulation of the interleukin 1 receptor-associated 
kinase 1 (IRAK1), which proved essential for epithelial TLR4 signalling in vitro [43]. 
Bacterial cells and soluble factors released by Bifidobacterium breve C50 (Bb) induced a 
dose-dependent inhibition of the chemokine CXCL8 secretion by epithelial cells (HT-29) 
driven by both AP-1 and NF-κB transcription pathways, which implies decreased 
phosphorylation of p38-MAPK and IκB-α molecules. In trinitro-benzene sulphonic acid 
(TNBS)-induced colitis in mice, soluble factors of this strain decreased the colitis score and 
inflammatory cytokine expression, by inhibiting phosphorylations involved in inflammatory 
processes and by exerting protective effects on DCs [44]. Bacterial signalling to NOD 
receptors has also been shown to inhibit the TLR2-driven activation of NF-κB signalling and 
its deficient functioning is associated with Crohn’s disease [45].  
 
Cytokine induction  
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Commensal, probiotic and pathogenic bacteria modulate cytokine production by epithelial 
and professional immune cells differently, contributing to the protective immune response 
against pathogen invasion and the regulation of TLR expression. Several studies indicate that 
some probiotics and commensal bacteria can stimulate protective immune responses to 
enhance resistance to microbial pathogens, which involved the induction of pro-inflammatory 
cytokines and chemokines production (e.g. TNF-α,IL-8, IL-12 and IFN-γ) [46]. For example, 
the probiotic strain L. casei Shirota has been shown to induce IL-12 and IFNγ expression in 
mouse splenocites, which could help fight against pathogens [47]. L. plantarum BFE 1685 
and the probiotic strain L. rhamnosus GG also lead to increased IL-8 production in response 
to S. Typhimurium in HT29 cells, indicating that these cells are sensitised by lactobacilli to 
enhance their defence against the pathogen [30]. L. reuteri 100-23 administered to mice 
induced a transient gene expression of pro-inflammatory cytokines and chemokines, 
including IL-1α, IL-6, IFN-γ inducible protein 10, and macrophage inflammatory protein 2 
[48]. Modulation of cytokine production by commensal bacteria and pathogens also 
influences TLR expression. For example, IFN-γ was found to increase mRNA and surface 
expression of TLR4 in human monocytes and macrophages, enhancing their responsiveness 
to LPS in terms of phosphorylation of IRAK (immediately downstream of the MyD88 
adapter protein), NF-kB DNA binding activity, and cytokine (TNF-α and IL-12) production 
[49]. This enhanced TLR4 expression probably contributes to pathogen recognition and 
killing by mononuclear phagocytes.  
Commensal and probiotic strains could also regulate the degree of immune activation in 
response to pathogens or other harmful antigens, preventing excessive inflammation. These 
regulatory effects may be mediated by the induction of regulatory and anti-inflammatory 
cytokine production (IL-10 and TGF-β), which trigger suppressive pathways via modulation 
of TLR-signalling and lymphocyte differentiation (described below). Several commensal and 
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probiotic strains have been shown to induce IL-10 in epithelial and immune cells in vitro and 
in vivo [50, 51]. In the epithelium, IL-10 triggers different anti-inflammatory mechanisms 
through JAK1/STAT3 and p38 MAPK-dependent pathways, and may also directly confer 
protection by regulating the endoplasmic reticulum stress response linked to the activation of 
NKκB pathway and production of reactive oxygen species, involved in chronic inflammatory 
pathologies [52]. TGF-β is produced at an early state of bacterial colonization in animal 
models [40] and induced by the intake of some probiotic strains (e.g. B. longum 2C and 46 
and B. lactis Bb-12) in human peripheral blood [53]. TGF-β may regulate inflammatory 
responses by inhibiting the TLR-induced NF-kB-dependent pro-inflammatory gene 
expression program through the induction of TLR2 degradation via Smad signalling [52]. It 
has been hypothesised that commensal bacteria produce a transient activation of NKκB 
pathway in epithelial cells that triggers IL-10 and TGF-β mediated responses in the 
epithelium and lamina propria, thus contributing to maintaining immune homeostasis to 
commensal bacteria in the gut. Moreover, studies in germ-free and pathogen-free mice have 
shown that microbial colonization induced the expression of antimicrobial peptides but 
down-regulated the expression of pro-inflammatory type I IFN related genes in the large 
intestine, which could be an additional mechanism to prevent excessive inflammation due to 
continuous microbial exposure [54]. 
 
Lymphocyte differentiation and regulatory T-cell generation  
Lymphocyte differentiation may also be influenced by certain probiotic strains and 
commensal bacteria contributing to the host’s defences against pathogen infection, but 
avoiding excessive immunostimulation, which would lead to tissue damage [55]. TLRs and 
co-stimulatory molecules expressed by DCs and the cytokine network are essential to the 
induction of a balanced differentiation of naïve T cells into effector T cells (Th1 and Th2) 
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and IgA-secreting B cells, required to fight off pathogens, as well as into regulatory T cells 
(Tr1 and Th3) required to control excessive inflammation (Fig. 2) [56].  
Probiotic and commensal bacteria induce different cytokine production by stimulation of DCs 
in comparison with pathogenic bacteria, which may explain their different effects on 
lymphocyte differentiation. For example, O'Mahony et al. [57] reported that commensal 
bacteria (Lactobacillus and Bifidobacterium) induced regulatory cytokine production (IL-10) 
by MLN and MLN-derived DCs cells, whereas pathogenic bacteria (Salmonella) induced 
Th1-polarizing cytokines (IL-12 and TNF-α). IL-10 production and CD83 expression were 
also induced by strains of the species B. bifidum, B. longum, and B. pseudocatenulatum in 
cord blood DCs, polarising the immune response toward a Th-2 profile [58]. B. breve 
BbC50SN supernatant also induced DC maturation by up-regulating the expression of CD83, 
as well as CD86 and HLA DR, and IL-10 production, which involved TLR2 interactions 
[59]. Probiotic strains of the product VSL#3, which include lactobacilli, streptococci and 
bifidobacteria, were also shown to influence DCs maturation. Individual strains displayed 
distinct immunomodulatory effects on DCs and the most marked anti-inflammatory effects 
were exerted by bifidobacteria, which up-regulated IL-10 production by DCs, decreased 
expression of the costimulatory molecules CD80 and CD40, and decreased IFN-γ production 
by T cells [60]. In addition, different strains of the same species may polarize immune 
responses in different directions via cytokine production regulation [50, 51]. While some B. 
longum strains induced a Th2 orientation with high levels of IL-4 and IL-10, both secreted by 
splenocytes, and of TGF-β gene expression in the ileum of germ-free mice inoculated with 
the bifidobacteria, other strains induced Th1 orientations with high levels of IFN-γ and TNF-
α splenocyte secretions [51].  
The induction of regulatory T cells by commensal and some probiotic bacteria may 
contribute to suppressing activation of the immune system and, thereby, to maintaining 
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immune homeostasis and tolerance to self and harmless exogenous antigens [61]. For 
example, strains of L. reuteri and L. casei, but not of L. plantarum were shown to prime 
human monocyte-derived DCs to trigger regulatory T-cell development [62]. These 
regulatory T cells produced increased levels of IL-10 and were able to inhibit the 
proliferation of bystander T cells in an IL-10-dependent fashion. The binding of both L 
reuteri and L. casei the C-type lectin, which is a DC-specific intercellular adhesion molecule 
3-grabbing non-integrin (DC-SIGN), was necessary to induce regulatory T cells [62]. B. 
infantis 35624 also induced regulatory T cells in mice, contributing to protecting the host 
against aberrant activation of the innate immune system in response to infection with 
Salmonella enterica serovar Typhimurium or injection with LPS [63].  In B. infantis-fed mice, 
a profound inhibition of infection and LPS-induced NF-κB activity, which preceded a 
reduction in S. enterica serovar Typhimurium numbers, and murine sickness behaviour 
scores, was detected. In addition, pro-inflammatory cytokine secretion, T-cell proliferation, 
and DC co-stimulatory molecule expression were significantly reduced. In contrast, 
CD4+CD25+Foxp3+ T cell numbers increased significantly in the mucosa and spleen of 
mice fed B. infantis. In addition, adoptive transfer of CD4+CD25+ T cells transferred the 
NFκB inhibitory activity. Transfer of probiotic-treated DCs to mice also protected against 2, 
4, 6-trinitrobenzenesulfonic acid-induced colitis, partially, via induction of CD4+ CD25+ 
regulatory cells [64]. The preventive effect of probiotic-pulsed DCs required MyD88, pattern 
recognition receptors (TLR2- and NOD2) -dependent signalling and the induction of CD4+ 
CD25+ regulatory cells in an IL-10-independent fashion. These effects were induced by L. 
salivarius Ls33 and L. rhamnosus Lr32 but not by L. acidophilus NCFM. In contrast, the 
capsular polysaccharide of the Gram-negative bacteria Bacteroides fragilis proved to be 
taken up by CD11c+ DC, leading to the production of IL-12 and increased Th1 response [65]. 
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Some probiotics and commensal bacteria may also activate local antigen presenting cells to 
enhance antigen presentation to B lymphocytes and increase secretory IgA production both 
locally and systemically, improving the host’s defences against pathogens [66]. However, in 
pathogen-free mice commensal-loaded DC alone did not induce systemic immune responses 
because the commensal-loaded DCs were restricted to the mucosal immune compartment by 
the MLN [25]. Thus, pathogen-free mice remained systemically ignorant of their commensal 
microbiota. In fact, induction of secretory IgA against commensal bacteria is induced by both 
T-independent and T-dependent pathways, while induction of IgA against noxious stimuli 
(e.g. cholera toxin) is highly T-help dependent, reflecting the involvement of different 
immune responses to harmless and harmful microbial stimuli.  
 
Concluding remarks 
Scientific evidence supports a role for the microbiota and some probiotics in mucosal 
immunity regulation by taking part in different key events of the immune response, from 
TLR signalling to lymphocyte differentiation into regulatory T cells. Altogether, these 
contribute to improving the host’s defences against harmful agents and to maintaining 
intestinal homeostasis. Accordingly, specific probiotic strains are acknowledged for their 
ability to increase the defences against acute infections, improve chronic inflammatory bowel 
conditions and induce tolerance to harmless environmental antigens. Nevertheless, the impact 
of probiotics on diverse disease conditions are more subtle than expected. Advances in the 
understanding of the mechanisms by which specific components of the gut microbiota induce 
tolerance or predispose to disease via interactions with specific molecules of the epithelium 
and the GALT would be of great help to identify the molecular targets of probiotics and the 
biomarkers of their effects, and to provide sounder evidences on their benefits on physiologic 
conditions and immune-mediated disorders. 
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Captions for figures 
Figure 1. Signalling pathways triggered by the interaction of diverse bacterial components 
with the epithelium and GALT. Intestinal epithelial cells and antigen presenting cells 
(macrophages and dendritic cells [DCs]) express pattern recognition receptors, including the 
cell surface TLRs 2, 4 and 5 and the intracellular TLRs 3, 7 and 9. Lipoteichoic acids (LTA) 
from Gram-positive bacteria, LPS from Gram-negative bacteria, dsRNA from virus, flagellin 
from bacteria, RNA homologous (e.g. resiquimod R848) and ssRNA from viruses, and CpG 
oligonucleotides from bacterial and viral DNA are recognized respectively by TLR2, 4, 3, 5, 
7 and 9. Upon-ligand binding, TLRs promote signal divergence via interactions with different 
adaptor proteins (MyD88, TIRAP [MAL], TRIF [TICAM1] and TRAM). MyD88 is used by 
all TLRs, except for TLR3; TIRAP I is used by TLR2 and 4, TRIF is used by TLR3 and 4 
and TRAM is used only by TLR4. These interactions activate three major signalling 
pathways: the nuclear factor (NF)-κB, the mitogen-activated protein kinases (MAPKs) and 
IRFs.  Common to all TLRs is activation of (NF)-kB and AP-1 through MAPKs, leading to 
the production of inflammatory cytokines and chemokines. Interferon regulatory factor (IRF) 
3 and 7 are also activated by TLR3, 7 and 9, leading to the production of type I IFNs (IFN-αs 
and IFN-β).  
 
Figure 2. Differentiation of naïve T cells into T effector and regulatory T cells 
subpopulations by TLR–activated DCs.  
 
 
